Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie

Sign up for our daily newsletter

Durata problems sharpen Bank of America’s view on St. Jude Medical, mantains ‘Buy’

November 23, 2012 9:10 am by | 0 Comments

Bank of America reiterated its Buy rating and $43 price objective on St Jude Medical (NYSE: STJ) as it updated its stance on shares based on Durata.

Bank of America said, "The cumulative impact of pipeline disappointments, communication missteps and FDA's intense regulatory scrutiny of Durata over the last six months has sent STJ into a steep decline with the stock off nearly 30% since its recent highs in the low $40s. The latest issue to hit the stock was the release Tuesday night of a less redacted version of a recent FDA 483, which suggested at least some incremental risk to Durata. At the current price of $31.37, we believe the market now discounts roughly a 50% probability of Durata being recalled. Our sensitivity analysis suggests downside to $24 if Durata is recalled and upside to $40 if no problems surface. We think the probability of a recall is well below 50% given our read of the 483."

St Jude Medical closed at $31.37 on Wednesday.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By David Johnson,

Visit website | More posts by Author